$SGHT

Badawi David sold $41K of SGHT

Badawi David (Chief Technology Officer) sold 7,418 shares of Sight Sciences, Inc. (SGHT) at $5.51 on 2026-07-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Badawi David
Published Jul 6, 2026, 11:34 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 6, 2026, 11:36 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$SGHT
Neutral
medium confidence
Mentioned
$SGHT
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SGHTNeutralLow
01

Why it matters

The disclosed sale is specific (shares, price, total value) and confirms the transaction occurred on 2026-07-06, but it does not include any new operational, financial, or regulatory development for the company.

02

Market read

Traders may briefly reassess SGHT sentiment due to insider selling, but the 10b5-1 framing limits fundamental read-through.

03

What to watch

The filing provides no reason for the sale, and 10b5-1 plans can be triggered regardless of near-term outlook; the net effect is usually sentiment-only unless paired with other disclosures.

Relevance 2/10Novelty 3/10Timing: Filed 2026-07-06 after-hours; relevant for next session sentiment/positioning.

Background

The article is a primary-source SEC Form 4 insider transaction for Sight Sciences, Inc.

Company-level read

Ticker impact

$SGHTNeutralMedium confidence
Context

Sight Sciences CTO Badawi David sold 7,418 shares on 2026-07-06 at $5.5080/share under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited near-term impact; any move would be sentiment-driven rather than fundamental.

Evidence & confidence

Form 4 insider sales under a 10b5-1 plan are typically pre-scheduled and often not interpreted as new negative information, especially without accompanying company-specific news.

Market effects

Minimal—no sector-wide regulatory, clinical, or commercial catalyst is disclosed.

None indicated; US-listed microcap insider transaction only.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can be read as a lack of conviction; traders may watch for follow-on sales or changes in insider behavior.

Key entities

  • Sight Sciences, Inc.

    Subject of the Form 4 insider transaction; ticker SGHT.

  • Badawi David

    Chief Technology Officer and officer/director who sold shares.

  • 10b5-1 plan

    Pre-arranged plan indicating the sale was scheduled in advance.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SGHTHighAI 8/10

FDA Broadens ‘Indications for Use’ for Sight Sciences’ TearCare System

Sight Sciences (SGHT) announced FDA expanded the TearCare System's use to improve meibomian gland function in adults with evaporative dry eye disease due to MGD. This makes TearCare the first treatment indicated for this purpose, according to the company. The update also includes optional debridement, enhancing its approach to treating the condition. SGHT reported Q2 2026 revenue growth and updated its full-year guidance earlier this month.

$SGHTMedAI 8/10

Sight Sciences, Inc.: TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease

Sight Sciences (SGHT) announced FDA approval for its TearCare System to improve meibomian gland function in patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD). This makes TearCare the first and only treatment indicated for this purpose, expanding its market potential. The company's CEO and a medical expert highlighted the significance of this milestone in dry eye disease treatment.

$SGHTHighAI 8/10

TearCare is the first and only treatment indicated to improve gland function in dry-eye patients

Sight Sciences (SGHT) announced that the FDA expanded the TearCare System's indication to include improving meibomian gland function in adults with evaporative dry eye disease due to MGD. This makes TearCare the first and only treatment with this indication, effective August 18, 2026. The update also incorporates optional debridement into the system's treatment approach.

$SGHTMedAI 8/10

TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease

Sight Sciences (SGHT) announced FDA expanded approval for its TearCare System, now the only treatment indicated to improve meibomian gland function in patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD). The update includes optional debridement, enhancing its comprehensive approach to treating MGD. According to the company, this milestone reflects its commitment to advancing dry eye disease treatment.

$SGHTMedAI 8/10

Sight Sciences (SGHT) Q2 2026 Earnings Call Transcript

Sight Sciences (SGHT) reported Q2 2026 revenue of $23.4M, up 20% y/y, driven by Interventional Glaucoma ($20.7M) and Interventional Dry Eye ($2.7M). Gross margin rose to 91% from 85%. Net loss was $4.4M. FY2026 revenue guidance raised to $88M-$92M; adjusted opex guidance lowered to $92M-$94M. Alcon patent appeal remains pending.